Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Eichhorst

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
Cancers|October 14, 2022
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression AnalysisAnke Schilhabel, Peter Jonas Walter, Paula Cramer, et al.
Haematologica|November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
British Journal of Haematology|November 22, 2018
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemiaOthman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III StudyArnon P Kater, John F Seymour, Peter Hillmen, et al.
Haematologica|October 30, 2020
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, et al.
European Journal of Haematology|April 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG RegistryNadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
Leukemia & Lymphoma|September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenanceNatali Pflug, Paula Cramer, Sandra Robrecht, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
Cancers|October 14, 2022
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression AnalysisAnke Schilhabel, Peter Jonas Walter, Paula Cramer, et al.
Haematologica|November 2, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, et al.
British Journal of Haematology|November 22, 2018
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemiaOthman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III StudyArnon P Kater, John F Seymour, Peter Hillmen, et al.
Haematologica|October 30, 2020
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, et al.
European Journal of Haematology|April 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG RegistryNadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, et al.
Leukemia & Lymphoma|September 19, 2022
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and olderFlorian Simon, Adam Giza, Sandra Robrecht, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
American Journal of Hematology|September 9, 2014
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationPetra Langerbeins, Raymonde Busch, Nadine Anheier, et al.
Leukemia & Lymphoma|September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenanceNatali Pflug, Paula Cramer, Sandra Robrecht, et al.
Pageof 12